Previous 10 | Next 10 |
My previous article forecast problems for selonsertib, as new research indicates that this drug targets mouse-specific pathways that are not present in humans. NASH cirrhosis trials continue to struggle. Intercept’s Ocaliva, a “NASH cirrhosis” drug candidate, is haile...
Market Assessment 2019 is seen as the year of NASH in the biotech industry. Intercept ( ICPT ) is expected to announce the top-line Phase 3 data readout for obeticholic acid in NASH fibrosis imminently. Likewise, top-line data readout is also expected in Q1/2019 from Conatus ( CNAT ). This s...
CAS Medical Systems (NASDAQ: CASM ) +54% on being acquired by Edwards Lifesciences. More news on: CAS Medical Systems, Inc., Ellie Mae, Inc., Coty Inc., Stocks on the move, Read more ...
Conatus Pharmaceuticals (NASDAQ: CNAT ) has completed enrollment in its Phase 2b clinical trial, ENCORE-LF , evaluating lead drug emricasan in patients with stable decompensated NASH cirrhosis. More news on: Conatus Pharmaceuticals, Healthcare stocks news, Read more ...
SAN DIEGO, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the completion of enrollment in ENCORE-LF, a Phase 2b clinical trial evaluating emricasan, the company’s first-in-class, orally-active pan-caspase inhibitor. “With screen...
Viking Therapeutics (NASDAQ: VKTX ) +8.4% and Madrigal Pharmaceuticals (NASDAQ: MDGL ) +3.3% after-hours as Gilead’s (NASDAQ: GILD ) study designed to evaluate a chronic liver disease drug failed to meet its primary endpoint ; GILD -3.6% . More news on: Viking Therapeutic...
NEW YORK, NY / ACCESSWIRE / January 30, 2019 / U.S. markets were mostly down Tuesday on the latest batch of corporate earnings and as investors await details from the Feds' two-day policy meeting. The Dow Jones Industrial Average was up 0.21 percent to close at 24,579.96, led higher by 3M and...
Gainers: OncoCyte (NYSEMKT: OCX ) +228% . Voyager Therapeutics (NASDAQ: VYGR ) +36% . Conatus Pharmaceuticals (NASDAQ: CNAT ) +34% . Zynerba Pharmaceuticals (NASDAQ: ZYNE ) +33% . HyreCar (NASDAQ: HYRE ) +21% . Sanmina (NASDAQ: SANM ) +18% . Woodward (NASDAQ: WWD ) +17% . J &a...
Biocept (NASDAQ: BIOC ) +17% on launching liquid biopsy kits intended to broaden use of its proprietary technology platform for high sensitivity detection of circulating tumor DNA. More news on: Biocept, Inc., Pareteum Corporation, Conatus Pharmaceuticals, Stocks on the move,...
SAN DIEGO, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced publications expanding on previously reported results from three of the company’s completed Phase 2 clinical trials. Mitchell Schiffman, M.D., is the lead author on a new pub...
News, Short Squeeze, Breakout and More Instantly...
Conatus Pharmaceuticals Company Name:
CNAT Stock Symbol:
NASDAQ Market:
SAN DIEGO, May 18, 2020 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that Institutional Shareholder Services Inc. (ISS) and Glass Lewis, two leading independent research and proxy advisory firms that provide institutional investors with voting assessment an...
SAN DIEGO, May 14, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the publication of data on HST 004, its patented, naturally-derived material for spinal disc repair ...
SAN DIEGO, May 11, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) app...